文献速递外周动脉疾病

抗增殖药物血管内技术减少CLTI股腘动脉干预后再干预

Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2025-06-04

结论认为紫杉醇药物技术可能与较低的大再干预和死亡相关。

要点

  • 风险校正后药物器械与大再干预减少相关(HR 0.53,95%CI 0.31-0.91)。
  • 合并膝下干预后,排除30天内失败者,两组结局无差异。

核心结论

  • 在因CLTI行孤立股腘动脉血管内治疗的患者中,药物涂层器械与3年大再干预和死亡较低相关。
  • 合并膝下血管内干预时,排除30天内血运重建失败者后,风险校正分析显示两组结局无差异。

研究设计与样本

  • BEST-CLI试验(前瞻性随机对照试验,比较手术与血管内血运重建治疗腹股沟下CLTI)的as-treated数据集分析。
  • 纳入341例患者共341例孤立股腘动脉血管内手术(药物器械186例,无药物器械155例),多数为组织缺损(66.3%)。
  • 另分析668例股腘动脉±膝下血管内干预(药物器械377例,无药物器械291例)。

主要发现

  • 排除30天内失败后结果相似。
  • 合并膝下干预的668例中,排除30天内血运重建失败者后,风险校正分析显示总体结局无差异。

临床怎么用

  • 对于CLTI合并孤立股腘动脉闭塞性疾病行血管内治疗的患者,可考虑使用紫杉醇药物技术。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Conflicting data exist regarding the benefits of paclitaxel-based endovascular interventions (ENDO-Drug) for patients with chronic limb-threatening ischemia (CLTI). This analysis aims to evaluate the effect of such therapy in the Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: The as treated dataset from the BEST-CLI Trial, a prospective randomized trial comparing surgical and endovascular revascularization for infrainguinal CLTI, was used to assess the association of ENDO-Drug (drug-coated balloons or drug-eluting stents) use and 3-year outcomes after initial technical success in the femoropopliteal (FP) segment. ENDO-Drug was compared with ENDO-No Drug interventions. Outcomes evaluated included major reinterventions (new bypass, interposition graft, thrombectomy, or thrombolysis), any reintervention, major adverse limb events/death, above-ankle amputations, and death. RESULTS: There were 341 isolated FP endovascular procedures (186 ENDO-Drug, 155 ENDO-No Drug) performed in 341 patients; the majority were for tissue loss (66.3%). On Kaplan-Meier unadjusted analysis, ENDO-Drug was associated with fewer major reinterventions (16.7% vs 29.7%; P = .026), but similar any reinterventions (43.3% vs 55.6%; P = .16), major adverse limb events/death (42.4% vs 53.2%; P = .12), above-ankle amputation (14.1% vs 11.4%; P = .52), and death (21.5% vs 25%; P = .77). On risk-adjusted analysis, ENDO-Drug was associated with fewer major reinterventions (hazard ratio, 0.53; 95% confidence interval, 0.31-0.91; P = .02) and lower death (hazard ratio, 0.52; 95% confidence interval, 0.3-0.91; P = .02). Results were similar when excluding failures within 30 days. When considering any concomitant infrapopliteal interventions, there were 668 FP with or without any infrapopliteal endovascular interventions (377 ENDO-Drug, 291 ENDO-No Drug) performed. On risk-adjusted analysis, after excluding those patients who experienced revascularization failure within 30 days of the index procedure, there were no differences in outcomes overall. CONCLUSIONS: In patients with CLTI and isolated FP disease treated using endovascular therapy, ENDO-Drug was associated with lower 3-year major reinterventions and death. Endovascular interventions using paclitaxel-based drug technology should be considered in patients with CLTI and FP occlusive disease.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Siracuse JJ, Kaufman JA, Farber A, et al. Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia. J Vasc Surg. 2025. PMID: 40464723. doi:10.1016/j.jvs.2025.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。